Zydus reports positive Phase II(b) EVIDENCES-X results for Saroglitazar Mg in MASH EP News Bureau Aug 31, 2026 Global trial met its primary endpoint of MASH resolution without worsening of fibrosis at week 52
Madrigal Pharmaceuticals poised for market dominance with Rezdiffra’s first full quarter… EP News Bureau Aug 12, 2024 As per the GlobalData report, as Rezdiffra secures its position as a first-line treatment for MASH, Madrigal Pharmaceuticals eyes…
